Wu Y., Völler S., Goulooze S.C., Allegaert K., Sherwin C.M. T., Rongen van A., Roofthooft D.W.E., Simons S.H.P., Tibboel D., Flint R.B., Anker van den J.N., Knibbe C.A.J. Novel maturation function to capture the maturation of hepatic clearance in Preterm and Term Neonates to older infants, children and Adults: application to paracetamol and metabolites PK.…
Vendel E., Noort van N., Vis P., Liefaard L., Dimelow R. Belimumab Pharmacokinetic Simulations to Select an Appropriate Subcutaneous Dosing Regimen to Treat Paediatric Patients with Active Lupus Nephritis. PAGE 2024 [Link to publication]
Wu Y., Allegaert K., Flint R.B., GouloozeS.C., Välitalo P.A.J., Hoog de M., Mulla H., Sherwin C.M.T., Simons S.H.P., Krekels E.H.J., Knibbe C.A.J., Völler S. When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers? Pharmaceutical Research 2024 [Link to publication].
Goulooze S.C, Vis P., Krekels E.H.J., Knibbe C.A.J. Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses. Expert Review of Clinical Pharmacology 2023 [Link to publication].
Engbers A.G.J., Völler S., Flint R.B., Goulooze S.C., de Klerk J., Krekels E.H.J., van Dijk M., Willemsen S.P., Reiss I.K.M., Knibbe C.A.J., Simons S.H.P. The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants. Clin Pharmacol Ther. 2022 [Link to publication]
Biselele T., Bambi J., Betukumesu D. M., Ndiyo Y., Tabu G., Kapinga J., Bola V, Makaya P., Tjabbes H., Vis P., Peeters-Scholte C.. A Phase IIa Clinical Trial of 2 ‑ Iminobiotin for the Treatment of Birth Asphyxia in DR Congo , a Low ‑ Income Country. Pediatr. Drugs. 22(1). 2020 [Link to publication].
Favie L. M. A., Peeters-Scholte C. M. P. C. D., Bakker A., Tjabbes H., Egberts T. C. G., van Bel F., Rademaker C. M. A., Vis P., Groenendaal F. Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. Pediatr. Res.: 2019. [Link to publication]
Brochot A., Kakuda T.N., Van De Casteele T., Opsomer M., Tomaka F.L., Vermeulen A. and Vis P., Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged >/=3 to <12 Years, CPT Pharmacometrics Syst Pharmacol., 4(7): 406-414. 2015. [Link to publication]
Krekels E.H., Jongh J.d., Lingen R.A.v., Marel C.D.v.d., Choonara I., Lynn A.M., Danhof M., Tibboel D. and Knibbe C.A., Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children, Clin Pharmacokinet., 50(1): 51-63, 2011. [Link to publication]
Muller A.E., Jongh J.d., Bult Y., Goessens W.H., Mouton J.W., Danhof M. and Anker J.N.v.d., Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks, Antimicrob Agents Chemother, 23: 23, 2007. [Link to publication]